Gilead’s Kite pens 10-target CAR-T tech deal with MaxCyte by Nick Paul Taylor Friday, March 1, 2019 The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.
Chutes & Ladders—Novartis lures UCSF cardiovascular scientist by Angus Liu Friday, August 18, 2017 UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
